Last 8 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.80 | — | 67.90 | — | 21.88 | 26.12 | 28.39 | 52.00 | — |
| — | — | +139.2% | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.88 | 0.61 | — | 1.41 | 0.93 | 1.32 | 1.30 | 1.26 | — |
| — | -53.7% | — | +12.2% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -78.7% | -40.9% | — | -11.7% | -10.5% | -9.3% | -11.9% | -17.0% | — |
| — | -337.7% | — | +31.1% | — | — | — | — | — | |
| ROA | -76.3% | -14.1% | -16.4% | -11.3% | -10.2% | -9.1% | -11.6% | -16.4% | -12.5% |
| — | -55.3% | -41.7% | +31.2% | +18.7% | — | — | — | — | |
| ROIC | -64.9% | — | — | -9.3% | -8.8% | -8.0% | -9.9% | -12.9% | — |
| — | — | — | +27.9% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 17.3% YoY to 13.33x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.01 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.40 | 13.33 | 5.22 | 0.66 | 10.40 | 16.12 | 26.23 | 90.42 | — |
| — | -17.3% | -80.1% | -99.3% | — | — | — | — | — | |
| Quick Ratio | 10.40 | 13.33 | 5.22 | 0.66 | 10.40 | 16.12 | 26.23 | 90.42 | — |
| — | -17.3% | -80.1% | -99.3% | — | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBridgeBio Oncology Therapeutics Inc.'s current P/E is 21.8x. The average P/E over the last 2 quarters is 44.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BridgeBio Oncology Therapeutics Inc.'s business trajectory between earnings reports.